References

inovmed

Инновационная медицина Кубани

Innovative Medicine of Kuban

2541-9897

Scientific Research Institute – Ochapovsky Regional Clinical Hospital No. 1

10.35401/2541-9897-2022-25-2-67-76

inovmed-539

Research Article

ОБЗОРЫ

REVIEWS

Применение клеток пуповинной крови и пуповины: достижения, проблемы и перспективы

Application of cells of cord blood and umbilical cord: achievements, challenges and perspectives

https://orcid.org/0000-0002-9766-1811

Гилевич

И. В.

Gilevich

I. V.

Гилевич Ирина Валериевна, к. м. н., заведующая лабораторией разработки и изучения новых технологий лечения заболеваний; ассистент кафедры онкологии с курсом торакальной хирургии ФПК и ППС

350086, Краснодар, ул. 1 Мая, д. 167

Краснодар

Irina V. Gilevich, Cand. Sci. (Med.), Head of the Laboratory for Development and Study of New Treatment Technologies; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists

1 Maya str., 167, Krasnodar, 350086

Krasnodar

giliv@list.ru

https://orcid.org/0000-0001-5912-8074

Поляков

И. С.

Polyakov

I. S.

Поляков Игорь Станиславович, к. м. н., первый заместитель главного врача; ассистент кафедры онкологии с курсом торакальной хирургии ФПК и ППС

Краснодар

Igor S. Polyakov, Cand. Sci. (Med.), First Deputy Chief Physician; Assistant Professor, Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists

Krasnodar

https://orcid.org/0000-0003-0572-1395

Порханов

В. А.

Porhanov

V. A.

Порханов Владимир Алексеевич, академик РАН, д. м. н., профессор, главный врач НИИ - ККБ № 1 им. проф. С.В. Очаповского; заведующий кафедрой онкологии с курсом торакальной хирургии ФПК и ППС

Краснодар

Vladimir A. Porhanov, Academician of Russian Academy of Sciences, Dr. Sci. (Med.), Professor, Chief Doctor; Head of Department of Oncology with the Course of Thoracic Surgery, Faculty of Advanced Training and Professional Retraining of Specialists

Krasnodar

https://orcid.org/0000-0003-1843-6518

Сторожук

А. П.

Storozhuk

A. P.

Сторожук Александр Петрович, д. м. н., главный врач; профессор кафедры фундаментальной и клинической биохимии

Краснодар

Alexander P. Storozhuk, Dr. Sci. (Med.), Head of Krasnodar Maternity Hospital, Professor of the Department of Fundamental and Clinical Biochemistry

Krasnodar

https://orcid.org/0000-0002-3276-9733

Завгородняя

А. Г.

Zavgorodnyaya

A. G.

Завгородняя Анна Германовна, студентка 6-го курса, лечебный факультет

Краснодар

Anna G. Zavgorodnyaya, 6th year student, Medical Faculty

Krasnodar

https://orcid.org/0000-0002-7773-9159

Коломийцева

Е. А.

Kolomiytseva

E. A.

Коломийцева Елена Анатольевна, биолог лаборатории разработки и изучения новых технологий лечения заболевания

Краснодар

Elena A. Kolomiytseva, Biologist, Laboratory for Development and Study of New Treatment Technologies

Krasnodar

https://orcid.org/0000-0001-7322-0459

Сотниченко

А. С.

Sotnichenko

A. S.

Сотниченко Александр Сергеевич, к. м. н., доцент кафедры патологической анатомии

Краснодар

Alexander S. Sotnichenko, Cand. Sci. (Med.), Associate Professor, Department of Pathological Anatomy

Krasnodar

Научно-исследовательский институт - Краевая клиническая больница № 1 им. проф. С.В. Очаповского; Кубанский государственный медицинский университетРоссияScientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1; Kuban State Medical UniversityRussian Federation

Кубанский государственный медицинский университет; Родильный дом г. КраснодараРоссияKuban State Medical University; Krasnodar Maternity HospitalRussian Federation

Кубанский государственный медицинский университетРоссияKuban State Medical UniversityRussian Federation

Научно-исследовательский институт - Краевая клиническая больница № 1 им. проф. С.В. ОчаповскогоРоссияScientific Research Institute - Ochapovsky Regional Clinical Hospital no. 1Russian Federation

2022

30062022

026776

2022

Гилевич И.В., Поляков И.С., Порханов В.А., Сторожук А.П., Завгородняя А.Г., Коломийцева Е.А., Сотниченко А.С.

Gilevich I.V., Polyakov I.S., Porhanov V.A., Storozhuk A.P., Zavgorodnyaya A.G., Kolomiytseva E.A., Sotnichenko A.S.

Данная работа распространяется под лицензией Creative Commons Attribution 4.0.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.innovmedkub.ru/jour/article/view/539

В обзоре представлены биологические аспекты применения пуповинной крови, как ценного источника клеток. Описаны отличительные особенности гемопоэтических стволовых клеток, клеток иммунной системы, мезенхимальных стволовых клеток. Проведен анализ результатов клинических исследований и разработок терапевтических подходов с помощью клеток пуповинной крови и пуповины в лечении различных заболеваний.

В настоящее время основными клиническими направлениями исследований пуповинной крови являются трансплантация гемопоэтических столовых клеток, клеточная иммунотерапия опухолевых заболеваний, лечение неврологических заболеваний и регенеративная медицина.

This review focuses on the biological aspects of the use of cord blood as a valuable source of cells. The distinctive features of hematopoietic stem cells, cells of the immune system, mesenchymal stem cells are described. The analysis of the results of clinical research and development of therapeutic approaches using cord blood cells and umbilical cord for the treatment of various diseases has been carried out.

Currently, the target area of cord blood research is hematopoietic stem cell transplantation, as well as cellular immunotherapy of tumor diseases, treatment of neurological diseases and regenerative medicine.

пуповинная кровьпуповинагемопоэтические стволовые клеткимезенхимальные стволовые клеткирегенеративная медицина

cord bloodumbilical cordhematopoietic stem cellsmesenchymal stem cellsregenerative medicine

References1

Романов Ю.А., Романов А.Ю. Ткани перинатального происхождения - уникальный источник клеток для регенеративной медицины. Часть I. Пуповинная кровь. Неонатология: новости, мнения, обучение. 2018;6(2):64-77. https://doi.org/10.24411/2308-2402-2018-00019

Romanov YuA, Romanov AYu. Tissues of perinatal origin is a unique source of cells for regenerative medicine. Part I. Cord blood. Neonatology: News, Opinions, Training. 2018;6(2):64-77. (In Russ.). https://doi.org/10.24411/2308-2402-2018-00019

Berglund S, Magalhaes I, Gaballa A, et al. Advances in umbilical cord blood cell therapy: the present and the future. Expert Opin Biol Ther. 2017;17(6):691-699. PMID: 28379044. https://doi.org/10.1080/14712598.2017.1316713

Berglund S, Magalhaes I, Gaballa A, et al. Advances in um-bilical cord blood cell therapy: the present and the future. Expert Opin Biol Ther. 2017;17(6):691-699. PMID: 28379044. https://doi.org/10.1080/14712598.2017.1316713

Topful M, Qetin i. Stem Cells in Cell Therapy and Regenerative Medicine. International OMICS eBooks; 2018. https://doi.org/10.4172/978-1-63278-021-8-22

Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraembryonic tissues. J R Soc Interface. 2010;7(Suppl 6):S689-706. PMID: 20739312. PMCID: PMC2988276. https://doi.org/10.1098/rsif.2010.0347.focus

Abdulrazzak H, Moschidou D, Jones G, et al. Biological characteristics of stem cells from foetal, cord blood and extraem- bryonic tissues. J R Soc Interface. 2010;7(Suppl 6):S689-706. PMID: 20739312. PMCID: PMC2988276. https://doi.org/10.1098/rsif.2010.0347.focus

Gluckman E. History of cord blood transplantation. Bone Marrow Transplant. 2009;44(10):621-626. PMID: 19802032. https://doi.org/10.1038/bmt.2009.280

Ballen KK, Gluckman E, Broxmeyer HE. Umbilical cord blood transplantation: the first 25 years and beyond. Blood. 2013;122(4):491-498. PMID: 23673863. PMCID: PMC3952633. http://dx.doi.org/10.1182/blood-2013-02-453175

Alatyyat SM, Alasmari HM, Aleid OA, et al. Umbilical cord stem cells: Background, processing and applications. Tissue Cell. 2020;65:101351. PMID: 32746993. https://doi.org/10.1016/j.tice.2020.101351

Gupta A, El-Amin 3rd SF, Levy HJ, et al. Umbilical cord- derived Wharton's jelly for regenerative medicine applications. J Orthop Surg Res. 2020;15(1):49. PMID: 32054483. PMCID: PMC7017504. https://doi.org/10.1186/s13018-020-1553-7

Zhu X, Tang B, Sun Z. Umbilical cord blood transplantation: Still growing and improving. Stem Cells Transl Med. 2021;Suppl 2:S62-S74. PMID: 34724722. PMCID: PMC8560197. https://doi.org/10.1002/sctm.20-0495

Hordyjewska A, Popiolek L, Horecka A. Characteristics of hematopoietic stem cells of umbilical cord blood. Cytotechnology. 2015;67(3):387-396. PMID: 25373337. PMCID: PMC4371573. https://doi.org/10.1007/s10616-014-9796-y

Yun HD, Varma A, Hussain MJ, et al. Clinical Relevance of Immunobiology in Umbilical Cord Blood Transplantation. J Clin Med. 2019;8(11):1968. PMID: 31739455. PMCID: PMC6912281. https://doi.org/10.3390/jcm8111968

Nomura A, Takada H, Jin CH, et al. Functional analyses of cord blood natural killer cells and T cells: a distinctive inter- leukin-18 response. Exp Hematol. 2001;29(10):1169-1176. PMID: 11602318. https://doi.org/10.1016/s0301-472x(01)00689-0

Романов Ю.А., Романов А.Ю. Ткани перинатального происхождения: уникальный источник клеток для регенеративной медицины. Часть II. Пупочный канатик. Неонатология: новости, мнения, обучение. 2018;6(3):54-73. https://doi.org/10.24411/2308-2402-2018-13002

Romanov YuA, Romanov AYu. Tissues of perinatal origin: a unique source of cells for regenerative medicine. Part II. Umbilical cord. Neonatology: News, Opinions, Training. 2018;6(3):54-73. (In Russ.). https://doi.org/10.24411/2308-2402-2018-13002

Dominici M, Le Blanc K, Mueller I, et al. Minimal cri¬teria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8(4):315-317. PMID: 16923606. https://doi.org/10.1080/14653240600855905

Silini AR, Di Pietro R, Lang-Olip I, et al. Perinatal Derivatives: Where Do We Stand? A Roadmap of the Human Placenta and Consensus for Tissue and Cell Nomenclature. Front Bioeng Biotechnol. 2020;8:610544. PMID: 33392174. PMCID: PMC7773933. https://doi.org/10.3389/fbioe.2020.610544

Torre P, Flores AI. Current Status and Future Prospects of Perinatal Stem Cells. Genes (Basel). 2020;12(1):6. PMID: 33374593. PMCID: PMC7822425. https://doi.org/110.3390/genes12010006

Forraz N, McGuckin CP. The umbilical cord: a rich and ethical stem cell source to advance regenerative medicine. Cell Prolif. 2011;44 Suppl 1:60-69. PMID: 21481046. PMCID: PMC6495455. https://doi.org/10.1111/j.1365-2184.2010.00729.x

Xie Q, Liu R, Jiang J, et al. What is the impact of human umbilical cord mesenchymal stem cell transplantation on clinical treatment? Stem Cell Res Ther. 2020;11(1):519. PMID: 33261658. PMCID: PMC7705855. https://doi.org/10.1186/s13287-020-02011-z

Blazar BR, Hill GR, Murphy WJ. Dissecting the biol¬ ogy of allogeneic HSCT to enhance the GvT effect whilst minimizing GvHD. Nat Rev Clin Oncol. 2020;17(8):475-492. PMID: 32313224. PMCID: PMC7901860. https://doi.org/10.1038/s41571-020-0356-4

Blazar BR, Hill GR, Murphy WJ. Dissecting the biol¬ ogy of allogeneic HSCT to enhance the GvT effect whilst mini-mizing GvHD. Nat Rev Clin Oncol. 2020;17(8):475-492. PMID: 32313224. PMCID: PMC7901860. https://doi.org/10.1038/s41571-020-0356-4

Stavropoulos-Giokas C, Dinou A, Papassavas A. The Role of HLA in Cord Blood Transplantation. Bone Marrow Res. 2012;2012:485160. PMID: 23097706. PMCID: PMC3477523. http://doi.org/10.1155/2012/485160

Kindwall-Keller TL, Ballen KK. Umbilical cord blood: The promise and the uncertainty. Stem Cells Transl Med. 2020;9(10):1153-1162. PMID: 32619330. PMCID: PMC7519764. https://doi.org/10.1002/sctm.19-0288

World Marrow Donor Association International Standards for Unrelated Hematopoietic Stem Cell Donor Registries. D3.1 Public webpages with cord blood banking practices as part of the 2019 work programme of the World Marrow Donor Association (WMDA) for the EU Third Health Programme (2014-2020). 2020:26. URL: https://wmda.info/wp-content/uploads/2021/01/WMDA-2020-Standards_AM1_Jan2021-1.pdf

Mayani H, Wagner JE, Broxmeyer HE. Cord blood re-search, banking, and transplantation: achievements, challenges, and perspectives. Bone Marrow Transplant. 2020;55(1):48-61. PMID: 31089283. https://doi.org/10.1038/s41409-019-0546-9

Song CG, Zhang YZ, Wu HN, et al. Stem cells: a promising candidate to treat neurological disorders. Neural Regen Res. 2018;13(7):1294-1304. PMID: 30028342. PMCID: PMC6065243. https://doi.org/10.4103/1673-5374.235085

Song CG, Zhang YZ, Wu HN, et al. Stem cells: a promis-ing candidate to treat neurological disorders. Neural Regen Res. 2018;13(7):1294-1304. PMID: 30028342. PMCID: PMC6065243. https://doi.org/10.4103/1673-5374.235085

Paton MCB, Wall DA, Elwood N, et al. Safety of allogeneic umbilical cord blood infusions for the treatment of neurological conditions: a systematic review of clinical studies. Cytotherapy. 2022;24(1):2-9. PMID: 34384698. https://doi.org/10.1016/j.jcyt.2021.07.001

Paton MCB, Wall DA, Elwood N, et al. Safety of alloge-neic umbilical cord blood infusions for the treatment of neurologi-cal conditions: a systematic review of clinical studies. Cytotherapy. 2022;24(1):2-9. PMID: 34384698. https://doi.org/10.1016/j.jcyt.2021.07.001

Balassa K, Rocha V. Anticancer cellular immunotherapies derived from umbilical cord blood. Expert Opin Biol Ther. 2018;18(2):121-134. PMID: 29103317. https://doi.org/10.1080/14712598.2018.1402002

Balassa K, Rocha V. Anticancer cellular immunothera¬pies derived from umbilical cord blood. Expert Opin Biol Ther. 2018;18(2):121-134. PMID: 29103317. https://doi.org/10.1080/14712598.2018.1402002

Mu YX, Zhao YX, Li BY, et al. A simple method for in vitro preparation of natural killer cells from cord blood. BMC Biotechnol. 2019;19(1):80. PMID: 31752805. PMCID: PMC6869212. https://doi.org/10.1186/s12896-019-0564-0

Wang Z, Wu Z, Liu Y, et al. New development in CAR-T cell therapy. J Hematol Oncol. 2017;10(1):53. PMID: 28222796. PMCID: PMC5320663. https://doi.org/10.1186/s13045-017-0423-1

Obajdin J, Davies DM, Maher J. Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer. Clin Exp Immunol. 2020;202(1):11-27. PMID: 32544282. PMCID: PMC7488126. https://doi.org/10.1111/cei.13478

Obajdin J, Davies DM, Maher J. Engineering of chime¬ric natural killer cell receptors to develop precision adoptive im-munotherapies for cancer. Clin Exp Immunol. 2020;202(1):11-27. PMID: 32544282. PMCID: PMC7488126. https://doi.org/10.1111/cei.13478

Liu E, Marin D, Banerjee P, et al. Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors. N Engl J Med. 2020;382(6):545-553. PMID: 32023374. PMCID: PMC7101242. https://doi.org/10.1056/NEJMoa1910607

Kulus M, Sibiak R, Stefanska K, et al. Mesenchymal Stem/Stromal Cells Derived from Human and Animal Perinatal Tissues-Origins, Characteristics, Signaling Pathways, and Clinical Trials. Cells. 2021;10(12):3278. PMID: 34943786. PMCID: PMC8699543. https://doi.org/10.3390/cells10123278

Mebarki M, Abadie C, Larghero J, et al. Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candidate for the development of advanced therapy medicinal products. Stem Cell Res Ther. 2021;12(1):152. PMID: 33637125. PMCID: PMC7907784. https://doi.org/10.1186/s13287-021-02222-y

Mebarki M, Abadie C, Larghero J, et al. Human umbilical cord-derived mesenchymal stem/stromal cells: a promising candi-date for the development of advanced therapy medicinal products. Stem Cell Res Ther. 2021;12(1):152. PMID: 33637125. PMCID: PMC7907784. https://doi.org/10.1186/s13287-021-02222-y

Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells continues to appear safe: An updated systematic review and meta-analysis. E Clinical Medicine. 2020;19:100249. PMID: 31989101. PMCID: PMC6970160. https://doi.org/10.1016/j.eclinm.2019.100249

Thompson M, Mei SHJ, Wolfe D, et al. Cell therapy with intravascular administration of mesenchymal stromal cells contin-ues to appear safe: An updated systematic review and meta-analysis. E Clinical Medicine. 2020;19:100249. PMID: 31989101. PMCID: PMC6970160. https://doi.org/10.1016/j.eclinm.2019.100249

Wu Y, Cao Y, Li X, et al. Cotransplantation of haploidentical hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132-138. PMID: 24185180. https://doi.org/10.1016/j.scr.2013.10.001

Wu Y, Cao Y, Li X, et al. Cotransplantation of haploidenti- cal hematopoietic and umbilical cord mesenchymal stem cells for severe aplastic anemia: successful engraftment and mild GVHD. Stem Cell Res. 2014;12(1):132-138. PMID: 24185180. https://doi.org/10.1016/j.scr.2013.10.001

Riordan NH, Morales I, Fernandez G, et al. Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2021;19(1):197. PMID: 29523171. PMCID: PMC5845260. https://doi.org/10.1186/s12967-018-1433-7

Riordan NH, Morales I, Fernandez G, et al. Clinical feasi-bility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med. 2021;19(1):197. PMID: 29523171. PMCID: PMC5845260. https://doi.org/10.1186/s12967-018-1433-7

Wang D, Niu L, Feng X, et al. Long-term safety of umbilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17(3):333-340. PMID: 27270729. https://doi.org/10.1007/s10238-016-0427-0

Wang D, Niu L, Feng X, et al. Long-term safety of um-bilical cord mesenchymal stem cells transplantation for systemic lupus erythematosus: a 6-year follow-up study. Clin Exp Med. 2017;17(3):333-340. PMID: 27270729. https://doi.org/10.1007/s10238-016-0427-0

Yin Y, Hao H, Cheng Y, et al. The homing of human umbilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice. Int Immunopharmacol. 2018;60:235-245. PMID: 29778021. https://doi.org/10.1016/j.intimp.2018.04.051

Yin Y, Hao H, Cheng Y, et al. The homing of human um-bilical cord-derived mesenchymal stem cells and the subsequent modulation of macrophage polarization in type 2 diabetic mice. Int Immunopharmacol. 2018;60:235-245. PMID: 29778021. https:// doi.org/10.1016/j.intimp.2018.04.051

Cai J, Wu Z, Xu X, et al. Umbilical Cord Mesenchymal Stromal Cell With Autologous Bone Marrow Cell Transplantation in Established Type 1 Diabetes: A Pilot Randomized Controlled Open-Label Clinical Study to Assess Safety and Impact on Insulin Secretion. Diabetes Care. 2016;39(1):149-157. PMID: 26628416. https://doi.org/10.2337/dc15-0171

Dilogo IH, Canintika AF, Hanitya AL, et al. Umbilical cord-derived mesenchymal stem cells for treating osteoarthritis of the knee: a single-arm, open-label study. Eur J Orthop Surg Traumatol. 2020;30(5):799-807. PMID: 31989258. https://doi.org/10.1007/s00590-020-02630-5

Kim YJ, Ahn HJ, Lee SH, et al. Effects of conditioned media from human umbilical cord blood-derived mesenchymal stem cells in the skin immune response. Biomed Pharmacother. 2020;131:110789. PMID: 33152947. https://doi.org/10.1016/j.bio-pha.2020.110789

Zhang J, Lv S, Liu X, et al. Umbilical Cord Mesenchymal Stem Cell Treatment for Crohn's Disease: A Randomized Controlled Clinical Trial. Gut Liver. 2018;12(1):73-78. PMID: 28873511. PMCID: PMC5753687. https://doi.org/10.5009/gnl17035

Sun Q, Huang Z, Han F, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal allografts: pilot results of a multicenter randomized controlled trial. J Transl Med. 2018;16(1):52. PMID: 29514693. PMCID: PMC5842532. https://doi.org/10.1186/s12967-018-1422-x

Sun Q, Huang Z, Han F, et al. Allogeneic mesenchymal stem cells as induction therapy are safe and feasible in renal al-lografts: pilot results of a multicenter randomized controlled trial. J Transl Med. 2018;16(1):52. PMID: 29514693. PMCID: PMC5842532. https://doi.org/10.1186/s12967-018-1422-x

Shi M, Liu Z, Wang Y, et al. A Pilot Study of Mesenchymal Stem Cell Therapy for Acute Liver Allograft Rejection. Stem Cells Transl Med. 2017;6(12):2053-2061. PMID: 29178564. PMCID: PMC5702514. https://doi.org/10.1002/sctm.17-0134

Стукань А.И., Гилевич И.В., Порханов В.А., и др. Патогенетические предпосылки использования клеточных технологий при поражении легких, ассоциированном с SARS-CoV-2. Инновационная медицина Кубани. 2020;(2):69-78. https://doi.org/10.35401/2500-0268-2020-18-2-69-78

Stukan AI, Gilevich IV, Porhanov VA, et al. Pathogenetic ra-tionale for the use of cell therapy in lung injury associated with SARS-CoV-2. Innovative Medicine of Kuban. 2020;(2):69-78. (In Russ.). https://doi.org/10.35401/2500-0268-2020-18-2-69-78

Shu L, Niu C, Li R, et al. Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells. Stem Cell Res Ther. 2020;11(1):361. PMID: 32811531. PMCID: PMC7432540. https://doi.org/10.1186/s13287-020-01875-5

Meng F, Xu R, Wang S, et al. Human umbilical cord-de-rived mesenchymal stem cell therapy in patients with COVID-19: a phase 1 clinical trial. Signal Transduct Target Ther. 2020;5(1):172. PMID: 32855385. PMCID: PMC7450163. https://doi.org/10.1038/s41392-020-00286-5

Lanzoni G, Linetsky E, Correa D, et al. Umbilical cord mesenchymal stem cells for COVID-19 acute respiratory distress syndrome: A double-blind, phase 1/2a, randomized controlled trial. Stem Cells Transl Med. 2021;10(5):660-673. PMID: 33400390. PMCID: PMC8046040. https://doi.org/10.1002/sctm.20-0472

The authors declare that there are no conflicts of interest present.